Drugs / BATOPROTAFIB
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT05541159 | Mar → Jul 2025 | impaired renal function disease | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1 | NCT05490030 | Mar → Jun 2025 | — | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1 | NCT04294160 | Jul 2020 → Sep 2024 | colorectal cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04330664 | Apr 2020 → Jul 2022 | cancer of unknown primary site, metastatic malignant neoplasm | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04185883 | Dec 2019 → Dec 2026 expected | cancer | Amgen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04000529 | Jul 2019 → Jan 2024 | colorectal cancer, esophageal squamous cell carcinoma, gastrointestinal stromal tumor, head and neck squamous cell carcinoma +1 | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03114319 | May 2017 → Jul 2025 | cutaneous melanoma, esophageal squamous cell carcinoma, gastrointestinal stromal tumor, head and neck squamous cell carcinoma +1 | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07468071 | Jun 2026 → Jun 2029 expected | — | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04699188 | Feb 2021 → Jan 2027 expected | colorectal carcinoma, non-small cell lung carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04292119 | May 2020 → Dec 2022 | non-small cell lung carcinoma, refractory malignant neoplasm | Massachusetts General Hospital | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BATOPROTAFIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650521 ↗ |
| Known as | PTPN11 INHIBITOR TNO155 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650521 ↗ |
| Known as | SHP2 INHIBITOR TNO155 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650521 ↗ |
| Known as | TNO155 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07468071 ↗ |
| Action | Inhibit | “Protein-tyrosine phosphatase 2C inhibitor” CHEMBL4650521 ↗1“SHP2 inhibitor TNO155” NCT03114319 ↗ |
| Modality | Small molecule | — CHEMBL4650521 ↗ |
| Route | Oral | “TNO155 for oral administration” NCT03114319 ↗ |
| Target | PTPN11 | “Protein-tyrosine phosphatase 2C inhibitor” CHEMBL4650521 ↗ |